Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDEL4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. The award, issued on November 25, 2025, is structured as a firm fixed-price delivery order with an ultimate completion date of December 17, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to establish regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial contracting capability as a critical pharmaceutical supplier within the federal military medical supply chain, with the parent PPV-G GEN V contract featuring a ceiling value of $499,999,999 and performance through December 31, 2036. The company's established track record includes the delivery of specialized pharmaceutical products ranging from oncology treatments to biologics and emergency medications across multiple therapeutic categories. As the sole prime contractor on this delivery order with no subcontractor relationships identified, DMS Pharmaceutical Group continues to fulfill the diverse pharmaceutical requirements necessary to support Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FDEL4?
SPE2DR26FDEL4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FDEL4 worth?
The government has obligated $10,485 on SPE2DR26FDEL4.
Is contract SPE2DR26FDEL4 an order under another contract?
Yes. SPE2DR26FDEL4 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEL4 competed?
The extent of competition for SPE2DR26FDEL4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award